Canaan Partners
http://www.canaan.com/homeCanaan Partners is a venture capital firm that invests in early stage technology and healthcare companies. Since its founding in 1987, Canaan has invested in more than 250 companies including DoubleClick and Match.com.
View Older Stories View More Recent Stories
-
Komprise Raises $37M to Fuel Growth and Advance Leadership in Unstructured Data Management
-
Kraken Appoints Dan Ciporin to Board of Directors
-
OncoResponse to Present at 41st Annual J.P. Morgan Healthcare Conference
-
neonVest Closes Seed Round Led by 7BC Venture Capital for Their SaaS-Based Startup Scaling Platform
-
Lynne Laube, Founder and Former CEO of Cardlytics, Joins Valor Ventures as Operating Partner
-
Pathios Therapeutics Appoints Jeanmarie Guenot, Ph.D., as Non-Executive Director
-
OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022
-
Fineqia Sees 7x Uplift in Investment Value in IDEO CoLab Ventures Fund I; No Exposure to FTX
-
Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022
-
Amid Rapid Growth, Lev Announces a Wave of Executive Hires, Appointing a Vice President of Marketing, Vice President of Product and Head of People
-
Form 13F-HR Canaan Partners X LLC For: Sep 30
-
Form 13F-HR Canaan Partners XI LLC For: Sep 30
-
OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo® (cemiplimab) in Patients with Advanced Cancer
-
Lily AI Closes $25M Series B to Bring the Language of the Customer Across the Entire Retail Value Chain
-
$16.7 Million Cash Out Refinance Loan Secured by Lev Brokers for TIR Equities in Birmingham, Michigan
-
Lev Secures $41.5 Million in Cannabis CRE Financing Across the U.S., Breaking Down Barriers to Federal Loans in the Market
-
Form 13F-HR Canaan Partners XI LLC For: Jun 30
-
Form 13F-HR Canaan Partners X LLC For: Jun 30
-
Form 13F-HR Canaan Partners IX LLC For: Jun 30
-
Lev Brokers Secure $2.3 Million Loan for Durham, NC Townhomes
-
$17.5 Million Construction-to-Permanent Financing Secured by Lev Brokers in Chesterfield, Michigan
-
Hank Debuts Platform to Connect Adults 55+ with In-Person Experiences and Community
-
Aziyo Biologics (AZYO) Appoints Dr. C. Randal Mills as Interim President and CEO
-
Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO
-
Lev Brokers Secure $11.7 Million Bridge Refinance Deal for Houston Multifamily Apartment Complex
-
Edge Impulse Announces Appointment of Simon Segars to Board of Directors
-
Jina AI Shapes Future of Search as CB Insights Names it in 100 Most Innovative AI Startups for Second Year Running
-
Dusty Robotics Raises $45M; Announces the Industry’s First Hardware, Software and Services Solution to Eliminate Construction Errors Through Advanced Robotics
-
Lev Announces $170 Million in New Funding from Parker89, Cross River Digital Ventures and Others
-
Form 13F-HR Canaan Partners XI LLC For: Mar 31
-
Form 13F-HR Canaan Partners X LLC For: Mar 31
-
Form 13F-HR Canaan Partners IX LLC For: Mar 31
-
Lev Brokers 1031 Exchange Sale of Dollar General and Family Dollar Properties for a Total of $3.5 Million
-
SUPERPLASTIC and Bored Ape Yacht Club Team up to Release First-Ever Vinyl Toy Collaboration in the NFT Space
-
Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at
-
Vivace Therapeutics Presents New Preclinical Data Highlighting Strong Synergistic Activity for Combination of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2
-
Vivace Therapeutics to Present New Data from Preclinical Combination Studies of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022
-
OncoResponse Announces Oral Presentation at Festival of Biologics World Immunotherapy Congress and World Antibody Congress 2022
-
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
-
Sovrn Adds Depth and Diversity to Its Board of Directors
-
RenoFi Releases Philadelphia Row Houses Renovation Guide
-
Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse
-
Form SC 13G Arbe Robotics Ltd. Filed by: Canaan Partners Israel (CPI) Cayman (L.P.)
-
Lev Lending Launches to Vertically Integrate Commercial Real Estate Financing
-
Form 13F-HR Canaan Partners X LLC For: Dec 31
-
Form 13F-HR Canaan Partners XI LLC For: Dec 31
-
Form 13F-HR Canaan Partners IX LLC For: Dec 31
-
Vivace Therapeutics Announces Issuance of New U.S. Composition of Matter Patents
-
Hyalex Orthopaedics Appoints Carl Vause, Orthopaedic Industry Veteran, as Chief Executive Officer and President and Names Mike Hawkins, Ph.D., Chief Technical Officer
-
CRE Veteran Wayne Potters Joins Lev as Managing Director to Launch First-of-its-Kind Digital CMBS Platform

